WRN dependency in dMMR/MSI-H endometrial cancer: Clinical perspectives of a novel synthetic lethality strategy
- PMID: 40043505
- DOI: 10.1016/j.ygyno.2025.02.021
WRN dependency in dMMR/MSI-H endometrial cancer: Clinical perspectives of a novel synthetic lethality strategy
Conflict of interest statement
Declaration of competing interest GF: honoraria: AstraZeneca; travel, accommodations, expenses: GlaxoSmithKline. IS: former employee of AstraZeneca. DL: consulting or advisory role: PharmaMar, AstraZeneca, Clovis Oncology, GlaxoSmithKline, MSD, Genmab, Seagen, Immunogen, Oncoinvest, Corcept Therapeutics, Sutro Biopharma, Novartis; speakers' bureau: AstraZeneca, Clovis Oncology, GlaxoSmithKline, MSD, PharmaMar, ImmunoGen, Seagen, Genmab; travel, accommodations, expenses: AstraZeneca, Clovis Oncology, GlaxoSmithKline. All the other authors declare no competing interest.
Publication types
LinkOut - more resources
Full Text Sources